Literature DB >> 17727325

Gene therapy of gynaecological diseases.

Anna Kanerva1, Mari Raki, Akseli Hemminki.   

Abstract

Gene therapy represents a potentially useful approach for the treatment of diseases refractory to conventional therapies. Various preclinical and clinical strategies have been explored for treatment of gynaecological diseases. Given the most severe unmet clinical need, much of the work has been performed with gynaecological cancers and ovarian cancer in particular. Although the safety of many treatment strategies has been demonstrated in early phase clinical trials, efficacy has been mostly limited heretofore. Major challenges include improving the vectors used with the aim of more effective and selective delivery. In addition, effective penetration into and spreading within advanced and complex tumour masses and metastases remains challenging. This review focuses on existing and developmental gene transfer applications for gynaecological diseases.

Entities:  

Mesh:

Year:  2007        PMID: 17727325     DOI: 10.1517/14712598.7.9.1347

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  7 in total

1.  Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.

Authors:  Daniel T Rein; Anne Volkmer; Gerd Bauerschmitz; Ines M Beyer; Wolfgang Janni; Markus C Fleisch; Anne Kathrin Welter; Dirk Bauerschlag; Thomas Schöndorf; Martina Breidenbach
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-01       Impact factor: 4.553

2.  Jagged1-expressing adenovirus-infected dendritic cells induce expansion of Foxp3+ regulatory T cells and alleviate T helper type 2-mediated allergic asthma in mice.

Authors:  Chu-Lun Lin; Huei-Mei Huang; Chia-Ling Hsieh; Chia-Kwung Fan; Yueh-Lun Lee
Journal:  Immunology       Date:  2018-11-29       Impact factor: 7.397

3.  A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer.

Authors:  Kenneth H Kim; Igor Dmitriev; Janis P O'Malley; Minghui Wang; Souheil Saddekni; Zhiying You; Meredith A Preuss; Raymond D Harris; Rosemarie Aurigemma; Gene P Siegal; Kurt R Zinn; David T Curiel; Ronald D Alvarez
Journal:  Clin Cancer Res       Date:  2012-04-17       Impact factor: 12.531

4.  A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Authors:  Kenneth H Kim; Igor P Dmitriev; Souheil Saddekni; Elena A Kashentseva; Raymond D Harris; Rosemarie Aurigemma; Sejong Bae; Karan P Singh; Gene P Siegal; David T Curiel; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-06-10       Impact factor: 5.482

5.  Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.

Authors:  S Chalikonda; M H Kivlen; M E O'Malley; X D Eric Dong; J A McCart; M C Gorry; X-Y Yin; C K Brown; H J Zeh; Z S Guo; D L Bartlett
Journal:  Cancer Gene Ther       Date:  2007-12-14       Impact factor: 5.987

6.  Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses.

Authors:  Anna Kanerva; Sergio Lavilla-Alonso; Mari Raki; Lotta Kangasniemi; Gerd J Bauerschmitz; Koichi Takayama; Ari Ristimäki; Renee A Desmond; Akseli Hemminki
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

7.  Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.

Authors:  Ahmad Mohammad Ashshi; Adel Galal El-Shemi; Igor P Dmitriev; Elena A Kashentseva; David T Curiel
Journal:  J Ovarian Res       Date:  2016-06-27       Impact factor: 4.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.